CAB-AXL-ADC not checked

BioAtla, Inc. · BA3011

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Conditionally active biologic anti-AXL antibody drug conjugate”In the company’s words, NCT04681131 on ClinicalTrials.gov
Tested for
Non-Small-Cell Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Main trialPhase 2
“The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC”In the company’s words, NCT04681131 on ClinicalTrials.gov
Other names
BA3011

Other drugs for Non-Small-Cell Lung Cancer

All 560 drugs for Non-Small-Cell Lung Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Completed 9 Jul 2025 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
Phase 1/2Completed 8 Jan 2025 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CAB-AXL-ADC

Following is part of Solo: you see every change to CAB-AXL-ADC the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in